PDE4A and autoimmune disease: For this reason, PDE4 inhibitors (especially rolipram, the first compound of this group) have been widely studied, and many research teams have demonstrated their inhibitory activity in inflammatory and immune cells, including T cells, and ensuing beneficial effects of these compounds in some autoimmune disorders or airway diseases [13,14,15].